Dinactin

Dinactin, an antibiotic ionophore produced by Streptomyces species, as an effective small molecule targeting Wnt/β-catenin signaling pathway in cancer cells. Dinactin shows marked inhibition of HCT-116 cell growth with an IC50 of 1.1 µM. Dinactin shows anti-proliferative activity against the cancer cells in apoptosis-independent manner. Dinactin is also an effective agent for the research of neuropathic pain[1].

Research Areas >> Cancer

Research Areas >> Infection

Signaling Pathways >> Stem Cell/Wnt >> Wnt

Research Areas >> Neurological Disease

Dinactin (compound 1) shows antibacterial activity with MIC values of 1, 0.039, 0.019, 0.078, 0.078, 0.156, 0.156, 0.156, 0.156 μg/ml for M.tuberculosis(ATCC 25177), S. epidermidis(ATCC 12228), M. luteus(ATCC10240), S. aureus(ATCC 35923), E. faecalis(ATCC 51299), B. subtilis(ATCC 11774), E. coli(ATCC 10536), P. aeruginosa(ATCC 10145), K. pneumonia(ATCC BAA-2146) strain, respectively[1]. Dinactin (0-100 µM) shows antitumor activity with IC50 values of 1.3, 1.1, 1.3, 1.5, 9.7, 80 µM for A549, HCT-116, T47D, MCF7, HepG2, HEK-293 cells, respectively[1]. Dinactin (0.5, 1, 2 µM; 24 h) induces morphological changes in a concentration dependent manner in HCT-116 cells[1]. inactin (0.5, 1, 2 µM; 24 h) effectively inhabits cell migration and invasion characteristics in HCT-116 cells[1].

[1]. Aehtesham Hussain, et al. Identification of dinactin, a macrolide antibiotic, as a natural product-based small molecule targeting Wnt/β-catenin signaling pathway in cancer cells. Cancer Chemother Pharmacol. 2019 Sep;84(3):551-559.